CPEA's Head: China's 12th Five-Year Plan For Biomedical Industry Focuses On Raising Standards
This article was originally published in PharmAsia News
Executive SummaryChina Pharmaceutical Enterprises Association President Yu Mingde revealed that China's 12th Five-Year Plan for the biomedical industry will focus on raising the quality of biopharmaceuticals and upgrading industrial standards
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.